Recipharm recognised in the CMO Leadership Awards 2018
Recipharm has been recognised in the CMO Leadership Awards for 2018. The awards, which recognise service excellence across pharmaceutical contract manufacturers, are organised by Life Science Leader and assess companies in six key areas including: quality, reliability, capabilities, expertise, compatibility and service.
Winners are identified through an Industry Standard Research (ISR) survey that obtains third-party feedback from sponsor companies. This year, more than 80 CMOs were measured against 26 performance indicators and ranked accordingly. As a result, Recipharm was selected as a winner in all six categories.
Thomas Eldered, CEO at Recipharm said, “We’re delighted to have again been rewarded for our efforts as part of the CMO Leaderships Awards. These awards in particular allow us to gain an uncensored insight into how our customers feel we’re performing so it’s great to be recognised year on year”.
“At Recipharm, we’re dedicated to offering not only quality development and manufacturing services, but also ensuring our customers benefit from our expertise and wide-ranging capabilities, so to be recognised in all six categories this year is a fantastic achievement for us.”
This year’s award ceremony was held in New York yesterday. To find out more about the CMO Leadership Awards please visit: http://www.cmoleadershipawards.com/.
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com, +44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.